Results 1 to 10 of about 4,918,610 (234)

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: 2 approved] [PDF]

F1000Research, 2021
Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation.
Ardyan Wardhana, Johanes Nugroho Eko Putranto, Pirhot Lambok Marnala Yosua Siahaan, Yoga Alfian Noor, Makhyan Jibril Al Farabi   +4 more
doaj   +6 more sources

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study [PDF]

Research and Practice in Thrombosis and Haemostasis, 2021
Background In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA).
Eva N. Hamulyák, Hanke M. G. Wiegers, Luuk J. J. Scheres, Barbara A. Hutten, Maria E. deLange, Anne Timmermans, Peter E. Westerweel, Marten R. Nijziel, Marieke J. H. A. Kruip, Marije ten Wolde, Paula F. Ypma, Frederikus A. Klok, Laurens Nieuwenhuizen, Sanne vanWissen, Marcel M. C. Hovens, Laura M. Faber, Pieter W. Kamphuisen, Harry R. Büller, Saskia Middeldorp   +18 more
doaj   +3 more sources

Definition of factor Xa inhibitor–related, life‐threatening gastrointestinal bleeding and guidance on when to use reversal therapy: A Delphi panel [PDF]

Journal of the American College of Emergency Physicians Open, 2023
Objective To define and contextualize life‐threatening gastrointestinal (GI) bleeding in the setting of factor Xa (FXa) inhibitor therapy and to derive a consensus‐based, clinically oriented approach to the administration of FXa inhibitor reversal ...
Gregory J. Fermann, Brooks D. Cash, Nayantara Coelho‐Prabhu, Marc Maegele, Roland Bingisser, Vinay Sehgal, Alexander T. Cohen, Anna Hundt Golden, Jon Russo, Mark Price, Allen Mangel, Bruce Koch, Mary J. Christoph, Truman J. Milling Jr.   +13 more
doaj   +2 more sources

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation [PDF]

Therapeutic Advances in Drug Safety, 2019
Background: Review of clinical data on andexanet alfa for the reversal of factor Xa (FXa) inhibitor associated anticoagulation. Data sources: In the present review, we identified articles via PubMed using the combined keywords andexanet alfa, apixaban ...
Elise Carpenter, Divita Singh, Eric Dietrich, John Gums   +3 more
doaj   +2 more sources

Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey [PDF]

Clinical and Applied Thrombosis/Hemostasis
Direct oral factor Xa inhibitors are replacing vitamin K-dependent antagonists as anticoagulation treatment in many clinical scenarios. Trauma centers are noting an increase in patients presenting on these medications.
Charles Fasanya MD, FRCS FACS, Abenámar Arrillaga MD FACS FCCP, Catherine Caronia MD, MBA, Lauren Rothburd BS, Tenzing Japhe BA, Younghee Hahn BS, Paul Joseph BS, Dajana Reci BA, Patricia Eckardt PhD, RN, FAAN   +8 more
doaj   +2 more sources

Warfarin versus factor Xa inhibitors in the long-term treatment of cerebral venous sinus thrombosis a single-center retrospective analysis

eNeurologicalSci, 2022
Long-term anticoagulation in the treatment of Cerebral Venous Sinus Thrombosis (CVST) has revolved around the use of warfarin. The relatively recent introduction of Direct Oral Anticoagulants (DOACs), such as Factor Xa inhibitors, in treating CVSTs ...
Alexei Christodoulides, Bradley N. Bohnstedt   +1 more
doaj   +1 more source

Performance Characteristics of DOAC Dipstick in Determining Direct Oral Anticoagulants in Urine

Clinical and Applied Thrombosis/Hemostasis, 2021
Testing for direct oral anticoagulants (DOACs) in patient urine may facilitate medical treatment decisions. The aim of this study was to investigate interobserver variability by 2 independent observers compared to laboratory staff in the visual ...
Job Harenberg MD, Andrea Martini MSc, Shanshan Du PhD, Sandra Krämer DMD, Christel Weiss PhD, Svetlana Hetjens PhD   +5 more
doaj   +1 more source

Optimisation of oral anticoagulants for patients with atrial fibrillation within 12 months after percutaneous coronary intervention: A meta-analysis and systematic review

International Journal of Cardiology: Heart & Vasculature, 2021
Background: The optimal antithrombotic strategy, especially regarding oral anticoagulants (OACs) for atrial fibrillation (AF) patients with bleeding and thrombosis risk after percutaneous coronary intervention (PCI), remains unknown.
Shuo Wang, Ying Liu, Linxin Wang, Haiqi Zuo, Yanfeng Tian, Yimeng Wang, Dechun Yin, Haiyu Zhang, Ye Tian   +8 more
doaj   +1 more source

The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra (Naja Species) Venoms

Frontiers in Immunology, 2021
African spitting cobras are unique among cobras for their potent anticoagulant venom activity arising from strong inhibition of Factor Xa. This anticoagulant effect is exerted by venom phospholipase A2 (Group I PLA2) toxins whose activity contributes to ...
Abhinandan Chowdhury, Abhinandan Chowdhury, Matthew R. Lewin, Matthew R. Lewin, Christina N. Zdenek, Rebecca Carter, Bryan G. Fry   +6 more
doaj   +1 more source

Prevention of venous thromboembolism with rivaroxaban and apixaban in orthopedic surgery [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2020
Numerous limitations and side effects of standard anticoagulants require administering new anticoagulant drugs. New peroral anticoagulants of Factor Xa inhibitor group have more advantages, the key ones being: substantial reductions in specific nutrition
Antonijević Nebojša, Kanjuh Vladimir, Živković Ivana, Jovanović Ljubica, Vukčević Miodrag, Apostolović Milan   +5 more
doaj   +1 more source